ReviewCurrent drug research reviews2026
Platelet-rich Plasma: A
Review in Current drug research reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid Arthritis (RA) is one of the most common inflammatory diseases, affecting millions of people worldwide, out of which 40% show poor clinical response while 5- 20% do not respond to current medications, including biologic and targeted therapies. Platelet- Rich Plasma (PRP), an autologous blood-derived product enriched with growth factors, has emerged as a new orthobiologic for the treatment of such non-responsive patients. The growth factors present in PRP influence various fundamental processes, including inflammation, angiogenesis, cell migration, and metabolism in RA. PRP alleviates the inflammatory response via suppression of nuclear factor-κβ beta and phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signalling pathway. It also modulates the intra-articular environment of the affected joints, characterised by the suppression of oxidative stress and synovial hyperplasia, and promotion of angiogenesis and chondrogenesis, thereby attenuating the arthritic changes in the synovium and cartilage. Till now, there appears to be a gap regarding uniformity in dosage regimens and treatment protocols among the studies demonstrating the efficacy of PRP in RA, and wellplanned studies are required to explore the therapeutic potential of this new orthobiologic treatment.
Indexed as
Identifiers
40873356What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.